Positive News SentimentPositive NewsNASDAQ:LYEL Lyell Immunopharma (LYEL) Stock Price, News & Analysis $1.17 -0.11 (-8.59%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.15▼$1.2750-Day Range$1.17▼$1.8852-Week Range$1.15▼$3.26Volume444,167 shsAverage Volume922,956 shsMarket Capitalization$298.28 millionP/E RatioN/ADividend YieldN/APrice Target$3.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Lyell Immunopharma alerts: Email Address Lyell Immunopharma MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside199.1% Upside$3.50 Price TargetShort InterestBearish13.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.57Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.85) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.70 out of 5 starsMedical Sector398th out of 910 stocksPharmaceutical Preparations Industry178th out of 426 stocks 3.3 Analyst's Opinion Consensus RatingLyell Immunopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageLyell Immunopharma has only been the subject of 2 research reports in the past 90 days.Read more about Lyell Immunopharma's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.25% of the float of Lyell Immunopharma has been sold short.Short Interest Ratio / Days to CoverLyell Immunopharma has a short interest ratio ("days to cover") of 15.9, which indicates bearish sentiment.Change versus previous monthShort interest in Lyell Immunopharma has recently decreased by 7.90%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLyell Immunopharma does not currently pay a dividend.Dividend GrowthLyell Immunopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LYEL. Previous Next 3.7 News and Social Media Coverage News SentimentLyell Immunopharma has a news sentiment score of 1.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lyell Immunopharma this week, compared to 1 article on an average week.Search Interest2 people have searched for LYEL on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Lyell Immunopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lyell Immunopharma insiders have not sold or bought any company stock.Percentage Held by Insiders25.10% of the stock of Lyell Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.05% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lyell Immunopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lyell Immunopharma are expected to decrease in the coming year, from ($0.85) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyell Immunopharma is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyell Immunopharma is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyell Immunopharma has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lyell Immunopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Lyell Immunopharma Stock (NASDAQ:LYEL)Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Read More LYEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LYEL Stock News HeadlinesSeptember 2, 2024 | americanbankingnews.comLyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Large Drop in Short InterestAugust 30, 2024 | 247wallst.com3 Penny Stocks to Buy With $500September 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 28, 2024 | globenewswire.comLyell Immunopharma Announces Participation in September Investor ConferencesAugust 24, 2024 | finance.yahoo.comRecent uptick might appease Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional owners after losing 32% over the past yearAugust 21, 2024 | uk.finance.yahoo.comLyell Immunopharma, Inc. (LYEL)August 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Lyell Immunopharma (LYEL) and Janux Therapeutics Inc (JANX)August 8, 2024 | markets.businessinsider.comLYEL Stock Earnings: Lyell Immunopharma Beats EPS for Q2 2024September 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 7, 2024 | finance.yahoo.comLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024August 6, 2024 | investorplace.com3 Biotech Stocks to Sell in August Before They Crash & BurnJune 26, 2024 | globenewswire.comLyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion TechnologyJune 3, 2024 | globenewswire.comLyell Immunopharma to Participate in the Goldman Sachs Global Healthcare ConferenceMay 13, 2024 | markets.businessinsider.comBank of America Securities Keeps Their Buy Rating on Lyell Immunopharma (LYEL)May 7, 2024 | globenewswire.comLyell Immunopharma to Participate in BofA Securities Health Care ConferenceMay 7, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Crispr Therapeutics AG (CRSP)May 7, 2024 | finance.yahoo.comLyell Immunopharma First Quarter 2024 Earnings: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)May 6, 2024 | investorplace.comLYEL Stock Earnings: Lyell Immunopharma Beats EPS for Q1 2024See More Headlines Receive LYEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LYEL CUSIPN/A CIK1806952 Webwww.lyell.com Phone650-695-0677FaxN/AEmployees270Year FoundedN/APrice Target and Rating Average Stock Price Target$3.50 High Stock Price Target$6.00 Low Stock Price Target$1.00 Potential Upside/Downside+199.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-234,630,000.00 Net Margins-389,368.50% Pretax Margin-389,368.50% Return on Equity-33.35% Return on Assets-29.07% Debt Debt-to-Equity RatioN/A Current Ratio16.19 Quick Ratio16.19 Sales & Book Value Annual Sales$54,000.00 Price / Sales5,523.68 Cash FlowN/A Price / Cash FlowN/A Book Value$2.21 per share Price / Book0.53Miscellaneous Outstanding Shares254,939,000Free Float190,949,000Market Cap$298.28 million OptionableOptionable Beta-0.53 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Richard D. Klausner M.D. (Age 72)Founder & Executive Chairman Comp: $80kDr. Lynn Seely M.D. (Age 65)Ph.D., President, CEO & Director Comp: $962.23kMr. Charles W. Newton (Age 53)Chief Financial Officer Comp: $744.74kMr. Stephen J. Hill (Age 54)Chief Operating Officer Comp: $775.97kDr. Gary Lee Ph.D. (Age 47)Chief Scientific Officer Comp: $889.68kMr. Matthew Lang J.D. (Age 48)Chief Business Officer, Chief Legal Officer & Corporate Secretary Comp: $596.25kProf. Stanley R. Riddell M.D.Founder & Scientific AdvisorDr. Crystal L. Mackall M.D. (Age 63)Founder & Scientific Advisor Nellie DilleryDirector of AccountingMs. Ellen RoseSenior Vice President of Communications & Investor RelationsMore ExecutivesKey CompetitorsAlectorNASDAQ:ALECErascaNASDAQ:ERASADC TherapeuticsNYSE:ADCTVerve TherapeuticsNASDAQ:VERVAllogene TherapeuticsNASDAQ:ALLOView All CompetitorsInstitutional OwnershipThe Manufacturers Life Insurance Company Bought 69,712 shares on 8/15/2024Ownership: 0.217%Susquehanna Fundamental Investments LLCBought 42,452 shares on 8/15/2024Ownership: 0.050%ProShare Advisors LLCSold 10,004 shares on 8/14/2024Ownership: 0.015%XTX Topco LtdSold 40,545 shares on 8/12/2024Ownership: 0.028%Dimensional Fund Advisors LPBought 26,635 shares on 8/9/2024Ownership: 0.016%View All Institutional Transactions LYEL Stock Analysis - Frequently Asked Questions How have LYEL shares performed this year? Lyell Immunopharma's stock was trading at $1.94 at the beginning of the year. Since then, LYEL stock has decreased by 39.7% and is now trading at $1.17. View the best growth stocks for 2024 here. How were Lyell Immunopharma's earnings last quarter? Lyell Immunopharma, Inc. (NASDAQ:LYEL) posted its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.02. The business earned $0.01 million during the quarter. Lyell Immunopharma had a negative trailing twelve-month return on equity of 33.35% and a negative net margin of 389,368.50%. When did Lyell Immunopharma IPO? Lyell Immunopharma (LYEL) raised $425 million in an IPO on Thursday, June 17th 2021. The company issued 25,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO. Who are Lyell Immunopharma's major shareholders? Top institutional shareholders of Lyell Immunopharma include WuXi AppTec Co. Ltd. (3.01%), TD Asset Management Inc (0.39%), Bank of New York Mellon Corp (0.26%) and Massachusetts Financial Services Co. MA (0.23%). View institutional ownership trends. How do I buy shares of Lyell Immunopharma? Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LYEL) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyell Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
